Literature DB >> 33392179

Two Decades of Global Progress in Authorized Advanced Therapy Medicinal Products: An Emerging Revolution in Therapeutic Strategies.

Roya Ramezankhani1,2, Shukoofeh Torabi1,2, Neda Minaei1,2, Hoda Madani1,2, Siamak Rezaeiani1,3, Seyedeh Nafiseh Hassani3,4, Adrian P Gee5, Massimo Dominici6, Daniela Nascimento Silva7,8, Hossein Baharvand3,4,9, Ensiyeh Hajizadeh-Saffar1,2,4.   

Abstract

The introduction of advanced therapy medicinal products (ATMPs) to the global pharma market has been revolutionizing the pharmaceutical industry and has opened new routes for treating various types of cancers and incurable diseases. In the past two decades, a noticeable part of clinical practices has been devoting progressively to these products. The first step to develop such an ATMP product is to be familiar with other approved products to obtain a general view about this industry trend. The present paper depicts an overall perspective of approved ATMPs in different countries, while reflecting the degree of their success in a clinical point of view and highlighting their main safety issues and also related market size as a whole. In this regard, published articles regarding safety, efficacy, and market size of approved ATMPs were reviewed using the search engines PubMed, Scopus, and Google Scholar. For some products which the related papers were not available, data on the relevant company website were referenced. In this descriptive study, we have introduced and classified approved cell, gene, and tissue engineering-based products by different regulatory agencies, along with their characteristics, manufacturer, indication, approval date, related regulatory agency, dosage, product description, price and published data about their safety and efficacy. In addition, to gain insights about the commercial situation of each product, we have gathered accessible sale reports and market size information that pertain to some of these products.
Copyright © 2020 Ramezankhani, Torabi, Minaei, Madani, Rezaeiani, Hassani, Gee, Dominici, Silva, Baharvand and Hajizadeh-Saffar.

Entities:  

Keywords:  ATMP; advanced therapy medicinal products; efficacy; market size; safety

Year:  2020        PMID: 33392179      PMCID: PMC7773756          DOI: 10.3389/fcell.2020.547653

Source DB:  PubMed          Journal:  Front Cell Dev Biol        ISSN: 2296-634X


  7 in total

Review 1.  Regenerative medicine clinical readiness.

Authors:  Satsuki Yamada; Atta Behfar; Andre Terzic
Journal:  Regen Med       Date:  2021-02-24       Impact factor: 3.806

2.  Retrospective Evaluation of Progenitor Biological Bandage Use: A Complementary and Safe Therapeutic Management Option for Prevention of Hypertrophic Scarring in Pediatric Burn Care.

Authors:  Karim Al-Dourobi; Alexis Laurent; Lina Deghayli; Marjorie Flahaut; Philippe Abdel-Sayed; Corinne Scaletta; Murielle Michetti; Laurent Waselle; Jeanne-Pascale Simon; Oumama El Ezzi; Wassim Raffoul; Lee Ann Applegate; Nathalie Hirt-Burri; Anthony S de Buys Roessingh
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-28

Review 3.  Regenerative Medicine Therapy in Malaysia: An Update.

Authors:  Siti A M Imran; M Haikal Aiman M Hamizul; Ahmad Amin Noordin Khairul Bariah; Wan Safwani Wan Kamarul Zaman; Fazlina Nordin
Journal:  Front Bioeng Biotechnol       Date:  2022-04-26

4.  Compliance in Non-Clinical Development of Cell-, Gene-, and Tissue-Based Medicines: Good Practice for Better Therapies.

Authors:  Luis Lopez-Navas; Sílvia Torrents; Rosario Sánchez-Pernaute; Joaquim Vives
Journal:  Stem Cells Transl Med       Date:  2022-08-23       Impact factor: 7.655

Review 5.  Vascularization in Bioartificial Parenchymal Tissue: Bioink and Bioprinting Strategies.

Authors:  Gabriel Alexander Salg; Andreas Blaeser; Jamina Sofie Gerhardus; Thilo Hackert; Hannes Goetz Kenngott
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

6.  Retrospective Analysis of Autologous Chondrocyte-Based Cytotherapy Production for Clinical Use: GMP Process-Based Manufacturing Optimization in a Swiss University Hospital.

Authors:  Virginie Philippe; Alexis Laurent; Nathalie Hirt-Burri; Philippe Abdel-Sayed; Corinne Scaletta; Valentine Schneebeli; Murielle Michetti; Jean-François Brunet; Lee Ann Applegate; Robin Martin
Journal:  Cells       Date:  2022-03-17       Impact factor: 6.600

7.  Mesenchymal Stromal Cell Therapy Improves Refractory Perianal Fistula in Crohn's Disease: Case Series Clinical Interventional Study.

Authors:  Massoud Vosough; Sepideh Nikfam; S Hukoofeh Torabi; Bahareh Sadri; Hadi Ahmadi Amoli; Ali Basi; Maryam Niknejadi; Nikoo Hossein-Khannazer; Seyedeh-Esmat Hosseini; Soura Mardpour; Vajiheh Azimian; Neda Jaroughi; Nasser Aghdami; Sepideh Nikfam; Hamid Reza Amirzehni; Amir Anushirvani; Reza Malekzadeh; Hossein Baharvand; Mehdi Mohamadnejad
Journal:  Cell J       Date:  2022-02       Impact factor: 3.128

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.